WangJY, DoudnaJA. CRISPR technology: A decade of genome editing is only the beginning. Science, 2023; 379(6629):eadd8643; doi: 10.1126/science.add8643
2.
UrnovFD. Genome editing B.C. (before CRISPR): Lasting lessons from the “old testament.”. CRISPR J, 2018; 1(1):34–46; doi: 10.1089/crispr.2018.29007.fyu
3.
KooninEV, MakarovaKS, WolfYI, et al.Evolutionary entanglement of mobile genetic elements and host defence systems: Guns for hire. Nat Rev Genet, 2020; 21(2):119–131; doi: 10.1038/s41576-019-0172-9
4.
FrangoulH, AltshulerD, CappelliniMD, et al.CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med, 2021; 384(3):252–260; doi: 10.1056/NEJMoa2031054
5.
VilligerL, JoungJ, KoblanL, et al.CRISPR technologies for genome, epigenome and transcriptome editing. Nat Rev Mol Cell Biol, 2024; doi: 10.1038/s41580-023-00697-6
6.
DurrantMG, FantonA, TyckoJ, et al.Systematic discovery of recombinases for efficient integration of large DNA sequences into the human genome. Nat Biotechnol, 2023; 41(4):488–499; doi: 10.1038/s41587-022-01494-w
7.
ZhangX, Van TreeckB, HortonCA, et al.Harnessing eukaryotic retroelement proteins for transgene insertion into human safe-harbor loci. Nat Biotechnol, 2024; doi: 10.1038/s41587-024-02137-y
8.
EickbushTH, EickbushDG. Integration, regulation, and long-term stability of R2 retrotransposons. Microbiol Spectr, 2015; 3(2):MDNA3-0011-2014; doi: 10.1128/microbiolspec.MDNA3-0011-2014
9.
WilkinsonME, FrangiehCJ, MacraeRK, et al.Structure of the R2 non-LTR retrotransposon initiating target-primed reverse transcription. Science, 2023; 380(6642):301–308; doi: 10.1126/science.adg7883
10.
ThawaniA, ArizaAJF, NogalesE, et al.Template and target-site recognition by human LINE-1 in retrotransposition. Nature, 2024; 626(7997):186–193; doi: 10.1038/s41586-023-06933-5
11.
MadiganV, ZhangF, DahlmanJE. Drug delivery systems for CRISPR-based genome editors. Nat Rev Drug Discov, 2023; 22(11):875–894; doi: 10.1038/s41573-023-00762-x
